Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference
Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) ("Gelteq" or the "Company"), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces that its Co-Founders, CEO Mr. Nathan Givoni and Executive Chairman Mr. Simon Szewach, will be participating in the Benchmark Company 13th Annual Discovery Investor Conference being held on Wednesday, December 11, 2024, at the New York Athletic Club in New York City.
紐約，2024年12月09日（環球新聞稿）-- Gelteq有限公司（納斯達克：GELS）（"Gelteq"或"公司"）是一家以臨床和科學爲基礎的公司，專注於開發和商業化用於處方藥、營養補充品、寵物護理及其他產品的白標凝膠遞送解決方案，宣佈其聯合創始人、首席執行官Nathan Givoni先生和執行主席Simon Szewach先生將參加Benchmark公司第13屆年度發現投資者會議，該會議將於2024年12月11日星期三在紐約市的紐約體育俱樂部舉行。
Mr. Givoni and Mr. Szewach will be hosting one-on-one meetings with analysts and investors throughout the day. To schedule a one-on-one meeting with them, attendees should contact their Benchmark Company representative. Investors can attend the conference by registering here.
Givoni先生和Szewach先生將在全天內與分析師和投資者進行一對一的會議。要安排與他們的一對一會議，參會者應聯繫其Benchmark公司代表。投資者可以通過在這裏註冊來參加會議。
About Gelteq Inc.
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. Gelteq is focused on advancing and commercializing its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. Gelteq's unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit .
關於Gelteq公司。
Gelteq（納斯達克：GELS）總部位於澳洲墨爾本，是一家以臨床和科學爲基礎的公司，專注於開發和商業化用於處方藥、營養補充品、寵物護理及其他產品的白標凝膠遞送解決方案。Gelteq專注於在五個核心領域內推進和商業化其遞送解決方案：藥品、非處方藥、營養補充品、動物藥物和體育營養。Gelteq的獨特配方直接解決了傳統藥物遞送方法所面臨的問題，例如吞嚥困難、不可口成分的味道和劑量控制。有關更多信息，請訪問。
Contact:
聯繫方式：
CORE IR
516-222-2560
PR@gelteq.com
核心紅外
516-222-2560
PR@gelteq.com
譯文內容由第三人軟體翻譯。
